Rempex Pharmaceuticals clinical trials
Acquired by Novartis, Jan 6, 2020 · source ↗
The registry lists 7 studies whose lead sponsor is Rempex Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 21, 2023.
- 7studies on the registry
- 0open to participants now
Before and after it joined Novartis
- First submitted before Rempex Pharmaceuticals became part of Novartis
- 7
- First submitted after Rempex Pharmaceuticals became part of Novartis
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Rempex Pharmaceuticals’ studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 7 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed686%
- Stopped early114%
Over the years
- 212
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)7 studies
Something wrong with this grouping? Tell us on the Novartis page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Novartis studies →
- Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IVWithdrawnNCT03291158Phase 1
Sponsor listed in the registry: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) · First submitted before Rempex Pharmaceuticals became part of Novartis
- Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult SubjectsCompletedNCT02073812Phase 1
Sponsor listed in the registry: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) · First submitted before Rempex Pharmaceuticals became part of Novartis
- The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal InsufficiencyCompletedNCT02020434Phase 1
Sponsor listed in the registry: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) · First submitted before Rempex Pharmaceuticals became part of Novartis
- Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult SubjectsCompletedNCT01897779Phase 1
Sponsor listed in the registry: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) · First submitted before Rempex Pharmaceuticals became part of Novartis
- Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult SubjectsCompletedNCT01751269Phase 1
Sponsor listed in the registry: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) · First submitted before Rempex Pharmaceuticals became part of Novartis
- Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in CombinationCompletedNCT01772836Phase 1
Sponsor listed in the registry: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) · First submitted before Rempex Pharmaceuticals became part of Novartis
- Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult SubjectsCompletedNCT01702649Phase 1
Sponsor listed in the registry: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) · First submitted before Rempex Pharmaceuticals became part of Novartis